Keryx Biopharmaceuticals Inc. (NASDAQ:KERX)’s share price dropped 1.1% during trading on Monday . The stock traded as low as $7.13 and last traded at $7.17, with a volume of 693,825 shares trading hands. The stock had previously closed at $7.25.

A number of brokerages have recently issued reports on KERX. BTIG Research restated a “sell” rating and set a $2.50 target price on shares of Keryx Biopharmaceuticals in a research report on Tuesday, March 29th. Maxim Group restated a “buy” rating and set a $9.00 target price (up from $7.00) on shares of Keryx Biopharmaceuticals in a research report on Friday. FBR & Co raised their target price on shares of Keryx Biopharmaceuticals from $10.00 to $13.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 30th. Cowen and Company restated a “hold” rating on shares of Keryx Biopharmaceuticals in a research report on Monday, March 28th. Finally, Zacks Investment Research lowered shares of Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, April 27th. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and seven have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $8.91.

The company’s 50 day moving average price is $6.24 and its 200-day moving average price is $4.91. The firm’s market capitalization is $755.55 million.

Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its quarterly earnings results on Thursday, April 28th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by $0.13. During the same quarter in the prior year, the company posted ($0.28) earnings per share. The company earned $6.80 million during the quarter, compared to analyst estimates of $6.63 million. The company’s quarterly revenue was up 466.7% on a year-over-year basis. On average, analysts expect that Keryx Biopharmaceuticals Inc. will post ($0.96) EPS for the current year.

A hedge fund recently bought a new stake in Keryx Biopharmaceuticals stock. Royce & Associates LLC purchased a new stake in shares of Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 341,725 shares of the biopharmaceutical company’s stock, valued at approximately $1,726,000. Royce & Associates LLC owned approximately 0.32% of Keryx Biopharmaceuticals at the end of the most recent reporting period.

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company’s product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.